Bellerophon Therapeutics (BLPH) is a clinical-stage biotherapeutics company. The company is focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Their mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
The company uses nitric acid for it’s INOpulse product, nitric acid can also be used to potentially treat coronavirus according to a study found, Novan is also looking into this.
The U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application, allowing the Company to initiate a Phase 3 study of INOpulse® inhaled nitric oxide (iNO) therapy in up to 500 patients infected with COVID-19.
What is a Investigational New Drug (IND)?
An Investigational New Drug Application (IND) is a request for authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.
The IND acceptance follows agreement by the FDA earlier this year to allow investigation treatment with INOpulse for COVID-19 patients under emergency expanded access. To date, over 50 patients with COVID-19 have received treatment with INOpulse under the care and supervision of their physicians.
The acceptance of our Phase 3 study for the treatment of patients infected with COVID-19 represents a major advancement in our clinical development program and enables us to gather the required clinical data for potential regulatory approval of INOpulse for patients with COVID-19, Under the emergency expanded access program, we have been encouraged by the improvements in patients with COVID-19 treated with INOpulse, reinforcing the potential for our propriety therapy to improve oxygenation in patients and halt the progression of the virus. We look forward to working with institutions across the United States to enroll patients into this important clinical trial and accelerate access to patients in need.
Fabian Tenenbaum, Chief Executive Officer at Bellerophon Therapeutics
Nitric oxide is a naturally produced molecule that is a powerful vasodilator improving arterial oxygenation and as part of the immune response to pathogens plays a key role in preventing viral replication. The proprietary INOpulse delivery system from Bellerophon Therapeutics is an investigational system that is portable and designed to deliver nitric oxide in a targeted, pulsatile manner that ensures accurate drug delivery and allows for use in outpatient settings outside of the hospital.
Conclusion: Bellerophon Therapeutics (BLPH), Novan (NOVN), Beyond Air (XAIR) Are good investments
The three companies here Bellerophon, Novan and Beyond Air all use nitric oxide and could be big players in the fight against coronavirus. I recommend you research and buy in long term.
